title: Does cardioplegia type affect outcome and survival in patients with advanced left ventricular dysfunction? Results from the CABG Patch Trial.
abstract: BACKGROUND
  There is controversy regarding which cardioplegic solution, temperature, and route of administration provides superior protection. The CABG Patch Trial enrolled a high-risk group of coronary artery disease patients with an ejection fraction of <36%. Thus, they constitute an ideal group to benefit most from optimal cardioplegic protection.
  
  
  RESULTS
  All patients randomized into the trial were compared with respect to the use of blood and crystalloid cardioplegia. In addition, a questionnaire was sent to surgeons requesting blood cardioplegic temperature and route. Patients receiving crystalloid cardioplegia versus those receiving blood cardioplegia were found to have significantly more operative deaths (2% versus 0.3%, P:=0.02), postoperative myocardial infarctions (10% versus 2%, P:<0.001), shock (13% versus 7%, P:=0. 013), and postoperative conduction defects (21.6% versus 12.4%, P:=0. 001). Despite this, early death (6% crystalloid versus 4% blood cardioplegia) and late death (24% crystalloid versus 21% blood cardioplegia) statistics were not significantly different. Patients receiving normothermic blood had less postoperative right ventricular dysfunction (10%) than did patients receiving cold blood (25%) or cold blood with warm reperfusion (30%) (P:=0.004). There was no significant difference in early or late death. Finally, patients who received combined antegrade and retrograde cardioplegia had significantly less inotrope use (71% versus 84%, P:=0.002), right ventricular dysfunction (23% versus 41%, P:=0.001), and postoperative balloon pump use (12% versus 19%, P:=0.02) than did those who received antegrade cardioplegia. There was no difference in survival.
  
  
  CONCLUSIONS
  Blood cardioplegia and combined antegrade and retrograde cardioplegia are superior to crystalloid and antegrade cardioplegia alone for postoperative morbidity. Despite this, there is no significant difference in early or late survival.
authors.affiliation: Department of Surgery, Baystate Medical Center, Springfield, MA, USA. JEFlack@aol.com
authors.forename: J E
authors.initials: JE
authors.lastname: Flack
authors.forename: J R
authors.initials: JR
authors.lastname: Cook
authors.forename: S J
authors.initials: SJ
authors.lastname: May
authors.forename: S
authors.initials: S
authors.lastname: Lemeshow
authors.forename: R M
authors.initials: RM
authors.lastname: Engelman
authors.forename: J A
authors.initials: JA
authors.lastname: Rousou
authors.forename: D W
authors.initials: DW
authors.lastname: Deaton
mesh_terms: D002314:Cardioplegic Solutions / Q000008:administration & dosage; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000379:methods*; D006324:Heart Arrest, Induced / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D015996:Survival Rate; D013696:Temperature; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000601:surgery*
chemical_list: D002314:Cardioplegic Solutions